12:00 AM
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BL-7040: Phase IIa started

BioLineRx disclosed in its 2Q12 earnings that it began an open-label, Israeli Phase IIa trial to evaluate 12 mg once-daily oral BL-7040 for 19-21 days followed by 40 mg once-daily oral BL-7040 for an additional 14 days...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >